ClinicalTrials.gg
RecruitingNCT07215650Updated Sep 2, 2026

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

A Phase 1 interventional study of Cizutamig in Generalized Myasthenia Gravis, sponsored by Candid Therapeutics. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Candid Therapeutics (part of UCB S.A.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Planned enrollment
10th of 18
44 · median 45
Started
2025
with 1 other
Phase 1
Only one
of the 18
Registered
15th of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 1, and was the 15th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.

Read the detailed description

This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of cizutamig in patients with Generalized Myasthenia Gravis.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old at the time of signing the Form (ICF);
  2. Diagnosed with MG, classified as MGFA Class II-IVa, and judged by the investigator as unlikely to require respiratory support during the study;
  3. At screening, the Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 5, with non-ocular items accounting for ≥ 50% of the total score, and GMG ≥ 11;
  4. Inadequate response to conventional therapies or lack of effective treatment options, defined as disease recurrence or progression despite treatment with , (e.g., azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, methotrexate), or biologics (e.g., rituximab), and/or lack of effective treatment methods.

Exclusion criteria

Exclusion Criteria:

  1. Any history of CAR-T or TCE therapy targeting any antigen or BCMA-targeted therapy;
  2. Use of any approved drugs not listed here within 12 weeks or 5 half-lives (whichever is longer) before screening, unless approved by the medical monitor;
  3. Participation in any trial involving non-biological agents within 4 weeks or 5 half-lives (whichever is longer) of the investigational product (IP) before screening;
  4. Participation in any investigational trial involving biological agents within 12 weeks or 5 half-lives (whichever is longer) of the IP before screening;
  5. Administration of within 4 weeks before screening;
  6. History of progressive multifocal leukoencephalopathy;
  7. History of primary immunodeficiency (e.g., hypogammaglobulinemia) or hereditary complement deficiency;
  8. Presence of one or more significant concurrent diseases, as judged by the investigator, including but not limited to:

    1. Poorly controlled diabetes
    2. Chronic kidney disease stages IIIb, IV, or V
    3. Severe chronic pulmonary disease (e.g., requiring supplemental oxygen) or respiratory failure
  9. Any severe medical condition or laboratory abnormality that, in the judgment of the investigator or medical monitor, would compromise the patient's safe participation and completion of the study or may affect protocol compliance or interpretation of study results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Cizutamig

    Drug: Cizutamig

Interventions

  • Cizutamig will be dosed according to the protocol

    Also known as: CND106

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events through end of study

    Time frame: Baseline to Month 12

  2. Changes from baseline in vital signs through end of study: body temperature

    Time frame: Baseline to Month 12

  3. Changes from baseline in vital signs through end of study: heart rate

    Time frame: Baseline to Month 12

  4. Changes from baseline in vital signs through end of study: respiratory rate

    Time frame: Baseline to Month 12

  5. Changes from baseline in vital signs through end of study: blood pressure

    Time frame: Baseline to Month 12

  6. Changes from baseline in vital signs through end of study: pulse oximetry

    Time frame: Baseline to Month 12

  7. Changes from baseline in ECG parameters through end of study: PR interval

    Time frame: Baseline to Month12

  8. Changes from baseline in ECG parameters through end of study: QRS interval

    Time frame: Baseline to Month 12

  9. Changes from baseline in ECG parameters through end of study: QTcF interval

    Time frame: Baseline to Month 12

  10. Changes from baseline in safety laboratory assessments through end of study: serum chemistry

    Time frame: Baseline to Month 12

  11. Changes from baseline in safety laboratory assessments through end of study: hematology

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Pharmacokinetic (PK) parameters for Cizutamig: Cmax

    Time frame: Baseline to Month 12

  2. PK parameters for Cizutamig: time of maximum concentration

    Time frame: Baseline to Month 12

  3. PK parameters for Cizutamig: area under the concentration-time curve

    Time frame: Baseline to Month 12

  4. PK parameters for Cizutamig: clearance

    Time frame: Baseline to Month 12

  5. PK parameters for Cizutamig: volume of distribution

    Time frame: Baseline to Month 12

  6. PK parameters for Cizutamig: half-life

    Time frame: Baseline to Month 12

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 10, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215650
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Sep 16, 2025
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

xiao dai
Contact
xiao@candidrx.com
+8618521520014

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cizutamig

Start the discussion